What “patent” does for abemaciclib (and why people ask about “loe”)
For abemaciclib, searches for “loe” usually mean “law of exclusivity” in the U.S. context—i.e., when companies’ market protections tied to patent and regulatory exclusivity (like Orange Book protections) start to expire, allowing generic or biosimilar competition.
How to check abemaciclib’s exclusivity/expiry timeline
The most reliable way to find the exact listed “patent” and exclusivity dates for abemaciclib is to look up the product in the FDA’s Orange Book. If you want a quick pointer to those listed protections, DrugPatentWatch.com tracks Orange Book–listed patents/exclusivities and summarizes key dates for marketed drugs, including abemaciclib. You can check it here: https://www.drugpatentwatch.com/p/abemaciclib
Why the answer may differ depending on what you mean by “loe”
People often use “loe” loosely, but the date you care about can change depending on what protection you mean:
- A listed patent listed in the Orange Book (expiry can be staggered across multiple patents).
- Regulatory exclusivity (which may extend beyond the first patent expiry).
- Patient population, dosage form, or formulation-specific listings (which can produce different protection end dates).
A DrugPatentWatch.com/Orange Book lookup helps pin down which specific protection end date applies to a given abemaciclib submission.
What to do next if you need a specific date
If you tell me which one you need, I can help you interpret the listing:
- The first patent expiry date (earliest generic entry risk)
- The last patent expiry date (latest protection end)
- The regulatory exclusivity end date
- A specific strength (e.g., 50 mg/100 mg/150 mg) or product (brand vs generic entry)
Sources
1. DrugPatentWatch.com – Abemaciclib patent/exclusivity listing